BCG-TERAPIYa PRI RAKE MOChEVOGO PUZYRYa — PLYuSY I MINUSY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

References

  1. Перельман М. И. Консультант врача. Фтизиатрия. М.: ГЭОТАР-Медиа; 2007.
  2. Colditz G. A., Brewer T. F., Berkey C. S. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. J. A. M. A. 1994; 271: 698—702.
  3. Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J. Med. Res. 1979; 70: 349—363.
  4. Aronson N. E., Santosham M., Comstock G. W. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska natives: A 60-year follow-up study. J. A. M. A. 2004; 291 (17): 2086— 2091.
  5. Rodrigues L. C., Diwan V K., Wheeler J. G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: A meta-analysis. Int. J. Epidemiol. 1993; 22: 1154—1158.
  6. Hart P. D., Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final Report of the Medical Research Council. Br. Med. J. 1977; 2: 293—295.
  7. Morales A., Eidinger D., Bruce A. W. Intracavitary bacillus Calmette—Guerin in the treatment of superficial bladder tumors. J. Urol. (Baltimore) 1976; 116 (2): 180—183.
  8. Shelley M. D., Kynaston H., Court J. et al. A systematic review of intravesical bacillus Calmette—Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. Br. J. Urol. Int. 2001; 88 (3): 209—216. http://www.ncbi.nlm.nih.gov/pubmed/11488731
  9. Bohle A., Jocham D., Bock P. R. Intravesical bacillus Calmette— Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 2003; 169 (1): 90—95. http://www.ncbi.nlm.nih.gov/pubmed/12478111
  10. Bohle A., Bock P. R. Intravesical bacillus Calmette—Guerin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004; 63 (4): 682—687.
  11. Sylvester R. J., van der Meijden A. P., Lamm D. L. Intravesical bacillus Calmette—Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168 (5): 1964—1970. http://www.ncbi.nlm.nih.gov/pubmed/12394686
  12. Huncharek M., Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder. Am. J. Clin. Oncol. 2003; 26 (4): 402—407.
  13. Huncharek M., Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette—Guerin immunotherapy. Am. J. Clin. Onol. 2004; 27 (5): 522—528. http://www.ncb.nlm.nih.gov/pubmed/15596924
  14. Lamm D. L., Blumenstein B. A., Crissman J. D. et al. Maintenance bacillus Calmette—Guerin immunotherapy for recurrfent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. (Baltimore) 2000; 163 (4): 1124—1129.
  15. Martinez-Pineiro J. A., Flores N., Isorna S. et al. for CUETO (Club Urologico Espanol De Tratamiento Oncologico). Longterm follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette—Guerin with a reduced dose of 27 mg in superficial bladder cancer. Br. J. Urol. Int. 2002; 89 (7): 671—680. http://www.ncbi.nlm.nih.gov/ pubmed/11966623
  16. Martinez-Pineiro J. A., Martinez-Pineiro L., Solsona E. et al. for Club Urologico Espanol De Tratamiento Oncologico (CUETO). Has a 3-fold decreased dose of bacillus Calmette—Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. (Baltimore) 2005; 174 (4, Pt 1): 1242—1247.
  17. Morales A. Oral administration of BCG. Can. Med. Assoc. J. 1979; 121 (11): 1447.
  18. Hudson M. A., Brown E. J., Ritchey J. K., Ratliff T. L. Modulation of fibronectin-mediated bacillus Calmette—Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 1991; 51 (14): 3726—3732/
  19. Kavoussi L. R., Brown E. J., Ritchey J. K., Ratliff T. L. Fibronectin-mediated Calmette—Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J. Clin. Invest. 1990; 85 (1): 62—67.
  20. Hudson M. A., Ritchey J. K., Catalona W. J. et al. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res. 1990; 50 (13): 3843—3847.
  21. Luo Y., Szilvasi A., Chen X. et al. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin. Diagn. Lab. Immunol. 1996; 3 (6): 761—768.
  22. Chung J. Y., Lee E. S., Lee W. J. et al. Analysis ofthe immunologic mechanism of intravesical bacillus Calmette—Guerin therapy for superficial bladder tumors: distribution and function of immune cells. J. Korean Med. Sci. 1993; 8 (2): 135—144.
  23. Kim C. I., Shin J. S., Kim H. I. et al. Production of tumor necrosis factor by intravesical administration of bacillus Calmette— Guerin in patients with superficial bladder cancer. Yonsei Med. J. 1993; 34 (4): 356—364.
  24. Bohle A., Nowe C., Ulmer A. J. et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette—Guerin immunotherapy. J. Urol. (Baltimore) 1990; 144 (1): 59—64.
  25. el-Demiry M. I., Smith G., Ritchie A. W. et al. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br. J. Urol. 1987; 60 (6): 543—548/
  26. See W. A., Chapman P. H. Heparin prevention of tumor cell adherence and implantation of injured urothelial surfaces. J. Urol. (Baltimore) 1987; 136: 386—388.
  27. Witjes J A. van der Meijden A. P. M., Doeburg W. et al. Influence of fibrin clot inhibitors on the efficacy of intravesical bacillus Calmette—Guerin in the treatment of superficial bladder cancer. Eur. Urol. 1993; 23: 366—370.
  28. Muttarak M., Lojanapiwat B., Chaiwun B., Wudhikarn S. Preoperative diagnosis of bilateral tuberculous epididymo-orchitis following intracvesical bacillus Calmette—Guerin therapy for superficial bladder carcinoma. Australas. Radiol. 2002; 46 (2): 183—185.
  29. Okadome A., Takeukchi F., Ishii T., Hiratsuka Y. Tuberculous epididymitis following intravesical bacillus Calmette—Guerin therapy. Nippon Hinyokika Gakkai Zasshi 2002; 93 (4): 580— 582.
  30. Ishizu K., Hirata H., Yano S. et al. Tuberculous epididymitis caused by intravesical BCG therapy: a case report. Hinyokika Kiyo 2003; 49 (9): 539—542.
  31. Bulbul M. A., Hijaz A., Beaini M. et al. Tuberculous epididymo-orchitis following intravesical BCG for superficial bladder cancer. J. Med. Liban. 2002; 50 (1—2): 67—69.
  32. Aust T. R., Massey J. A. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette—Guerin immnotherapy. Int. J. Urol. 2005; 12 (10): 920—921.
  33. Falkensammer C., Gozzi C., Hager M. et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacilli Calmette—Guerin therapy for superficial bladder carcinoma. Urology 2005; 65 (1): 175.
  34. Shigehara K., Kobori Y., Amano T., Takemae K. Bilateral tuberculous epididymitis after intravesical bacillus Calmette— Guerin therapy. Hinyokika Kiyo 2005; 51 (12): 839—842.
  35. Koizumi T., Nakanishi R., Taue R. et al. Case of tuberculous epididymitis caused by intravesical BCG therapy. Hinyokika Kiyo 2008; 54 (9): 625—627.
  36. Hoag N., Pommerville P. J., Kibsey P. C. et al. Tuberculous epididymitis following intravesical bacillus Calmette—Guerin immunotherapy. Can. J. Urol. 2009; 16 (2): 4589—4591.
  37. Sharma V. K., Sethy P. K., Dogra P. N. et al. Primary tuberculosis of glans penis after intravesical bacillus Calmette—Guerin immunotherapy. Indian J. Dermatol. Venereol. Leprol. 2011; 77 (1): 47—50.
  38. Foster D. R. Miliary tuberculosis following intravesical BCG treatment. Br. J. Radiol. 1997; 70 (832): 429.
  39. Gupta R. C., Lavengood R. Jr., Smith J. P. Miliary tuberculosis due to intravesical bacillus Calmette—Guerin therapy. Chest 1988; 94 (6): 1296—1298.
  40. Kesten S., Title L., Mullen B., Grossman R. Pulmonary disease following intravesical BCG treatment. Thorax 1990; 45 (9): 709—710.
  41. Palayew M., Briedis D., Libman M. et al. Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue. Chest 1993; 104 (1): 307—309.
  42. LeMense G. P., Strange C. Granulomatous pneumonitis following intravesical BCG. What therapy is needed? Chest 1994; 106 (5): 1624—1626.
  43. Hughes R. A., Allard S. A., Maini R. N. Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. Ann. Rheum. Dis. 1989; 48 (5): 432—434.
  44. Rozenblit A., Wassernan E., Marin M. L. et al. Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette—Guerin therapy. Am. J. Roentgenol. 1996; 167 (3): 711—713.
  45. Leebeek F. W., Ouwendijk R. J., Kolk A. H. et al. Granulomatous hepatitis caused by bacillus Calmette—Guerin (BCG) infection after BCG bladder instillation. Gut 1996; 38 (4): 616—618.
  46. Sharma N., Prescott S. BCG vaccine in superficial bladder cancer. Br. Med. J. 1994; 308 (6932): 801—802.
  47. Lamm D. L. Complications of bacillus Calmette—Guerin immunotherapy. Urol. Clin. N. Am. 1992; 19 (3): 565—572.
  48. Griggs H., Cammarata S. K. Acute mental changes in a 68-year-old man with bladder cancer. Chest 1998; 114 (2): 621—623.
  49. Bohle A., Jocham D. Intravesical immunotherapy with bacillus Calmette—Guerin. Facts figures and results. München: Urban & Fischer; 2000.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies